

## Lupin brings generic antibiotic inhalation solution in US market

14 June 2018 | News

**The company's Tobramycin Inhalation Solution USP, 300 mg/5 ml, is the generic version of Novartis Pharmaceuticals Corporation's Tobi 300 mg/5 ml**



Drug firm Lupin today said it has launched its antibiotic Tobramycin inhalation solution in the US market.

The company has launched the product as it has received an approval from the US Food and Drug Administration (USFDA) earlier, Lupin said.

The company's Tobramycin Inhalation Solution USP, 300 mg/5 ml, is the generic version of Novartis Pharmaceuticals Corporation's Tobi 300 mg/5 ml, it added.

The product is indicated for the management of cystic fibrosis patients with P aeruginosa, Lupin said.

As per IQVIA MAT April 2018 data, Tobramycin inhalation solution USP, 300 mg/5 ml, had annual sales of nearly USD 99 million in the American market, it added.